Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma.

Diffuse malignant gliomas, the most common type of brain tumor, carry a dire prognosis and are poorly responsive to initial treatment. The response to treatment is typically evaluated by measurements obtained from radiographic images several months after the start of treatment; therefore, an early biomarker of tumor response would be useful for making early treatment decisions and for prognostic information. Thirty-four patients with malignant glioma were examined by diffusion MRI before treatment and 3 weeks later. These images were coregistered, and differences in tumor-water diffusion values were calculated as functional diffusion maps (fDM), which were correlated with the radiographic response, time-to-progression (TTP), and overall survival (OS). Changes in fDM at 3 weeks were closely associated with the radiographic response at 10 weeks. The percentage of the tumor undergoing a significant change in the diffusion of water (V(T)) was different between patients with progressive disease (PD) vs. stable disease (SD) (P < 0.001). Patients classified as PD by fDM analysis at 3 weeks were found to have a shorter TTP compared with SD (median TTP, 4.3 vs. 7.3 months; P < 0.04). By using fDM, early patient stratification also was correlated with shorter OS in the PD group compared with SD patients (median survival, 8.0 vs. 18.2 months; P < 0.01). On the basis of fDM, tumor assessment provided an early biomarker for response, TTP, and OS in patients with malignant glioma. Further evaluation of this technique is warranted to determine whether it may be useful in the individualization of treatment or evaluation of the response in clinical protocols.

[1]  S B Green,et al.  The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Le Bihan,et al.  Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. , 1988, Radiology.

[3]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[5]  J. Cairncross,et al.  Malignant glioma--timing of response to radiation therapy. , 1993, International journal of radiation oncology, biology, physics.

[6]  A. Chvátal,et al.  Extracellular Volume Fraction and Diffusion Characteristics during Progressive Ischemia and Terminal Anoxia in the Spinal Cord of the Rat , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  M. Prados,et al.  Radiation response and survival time in patients with glioblastoma multiforme. , 1996, Journal of neurosurgery.

[8]  P. Basser,et al.  Diffusion tensor MR imaging of the human brain. , 1996, Radiology.

[9]  Charles R. Meyer,et al.  Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations , 1997, Medical Image Anal..

[10]  J. Slattery,et al.  Chemotherapy response criteria in malignant glioma , 1997, Neurology.

[11]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[12]  Response and progression in recurrent malignant glioma. , 1999 .

[13]  J. M. Taylor,et al.  Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. , 2000, Journal of the National Cancer Institute.

[14]  D. Louis,et al.  Glioma classification: a molecular reappraisal. , 2001, The American journal of pathology.

[15]  S. Takashima,et al.  Head and neck lesions: characterization with diffusion-weighted echo-planar MR imaging. , 2001, Radiology.

[16]  Benedick A Fraass,et al.  Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Daniel E. Hall,et al.  Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy. , 2002, Molecular imaging.

[18]  Usha Sinha,et al.  In vivo diffusion‐weighted MRI of the breast: Potential for lesion characterization , 2002, Journal of magnetic resonance imaging : JMRI.

[19]  David Moher,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. , 2003, Radiology.

[20]  T. Golub,et al.  Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.

[21]  Alexander de Vries,et al.  Preliminary Results on the Influence of Chemoradiation on Apparent Diffusion Coefficients of Primary Rectal Carcinoma Measured by Magnetic Resonance Imaging , 2003, Strahlentherapie und Onkologie.

[22]  Stephan E Maier,et al.  Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Bradford A Moffat,et al.  The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  Usha Sinha,et al.  In vivo diffusion tensor imaging of the human prostate , 2004, Magnetic resonance in medicine.

[25]  D. Ruppert.  The Elements of Statistical Learning: Data Mining, Inference, and Prediction , 2004 .

[26]  T. Takahara,et al.  Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. , 2004, Radiation medicine.

[27]  Bradford A Moffat,et al.  Therapeutic Efficacy of DTI-015 using Diffusion Magnetic Resonance Imaging as an Early Surrogate Marker , 2004, Clinical Cancer Research.

[28]  R. Gillies,et al.  Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. , 2004, Neoplasia.

[29]  D. Hadley,et al.  Imaging Response to Chemotherapy with RMP-7 and Carboplatin in Malignant Glioma: Size Matters but Speed does not , 2002, Journal of Neuro-Oncology.

[30]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[31]  Bradford A Moffat,et al.  Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[33]  David A Bluemke,et al.  Assessment of Response of Uterine Fibroids and Myometrium to Embolization Using Diffusion-Weighted Echoplanar MR Imaging , 2005, Journal of computer assisted tomography.